v3.26.3
REVENUE RECOGNITION (Tables)
9 Months Ended
Sep. 30, 2026
Revenue from Contract with Customer [Abstract]  
SCHEDULE OF DISAGGREGATED BY PRODUCT

Revenue disaggregated by product for the three and nine months ended September 30, 2026 and 2025 is as follows:

 

Product            
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
Product  2026   2025   2026   2025 
ARBLI™ (SCN-102, Losartan Potassium Oral Suspension)  $329,783   $-   $729,747   $- 
REZENOPY™ (naloxone HCl nasal spray, 10 mg)   924,794    -    924,794    - 
Pharmaceutical product resale   -    590,050    -    600,308 
Total revenues  $1,254,577   $590,050   $1,654,541   $600,308